Synovio Therapeutics
Drug Candidate for Osteoarthritis Therapy
Startup Pre-Seed Health Tech & Life Sciences Est. 2025
🌐 Website
Total Raised
Undisclosed
Pre-Seed
Last Round
Undisclosed
1 rounds
Investors
1
1 public
Team
1
1-10 employees
Confidence
58/100
About
Synovio Therapeutics develops a novel small molecule, Fenchone 1D, a specific agonist to the CB2 receptor as a drug candidate for Osteoarthritis therapy.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business Model
B2C
Funding & Events
Sep 2025
Pre-Seed Undisclosed
Israel Innovation Authority (Lead)
Details
Product Stage
R&D
Employees
1-10
Exact Count
1
Founded
2025
Locations
Israel
Links
Website
synoviotx.com/
Admin
Last Update
Oct 21, 2025
Verified by
Yanina Wainscheinker
Missing
sector, tags, logo, description, video or image, news, markets, external profiles, not claimed
Team (1)
adi Sagiv Meister
Founder
Founder
Internal
Created by
Dana Arnon (danaa@sncentral.org)
Created
2025-09-18T00:00:00.000Z
Finder · Synovio Therapeutics · 2026